Movement Alert｜PHARMARON Rises 4.85% in Regular Trading, CXO Rebound and Completed Block Transfer Ease Overhang

Market Focus10-20

On October 20, PHARMARON rose 4.85% in Regular Trading, trading at HK$27.6, with turnover of HK$85.21 million.

The move coincided with a broader rebound in the CXO segment, as sentiment toward innovative drugs and related supply chains improved, while uncertainty tied to a previously announced 1.00% share transfer was partially cleared after the transaction was completed.

Background disclosures show the shareholder transfer involved 18.373 million A shares at RMB38.89 per share, for total proceeds of about RMB715 million, with the allotted shares placed with 13 institutional investors and subject to a six-month lock-up. After the transfer, the combined stake of the actual controllers and parties acting in concert fell to 16.52%, but control did not change. The company is also scheduled to review third-quarter results on October 27, while an August broker note maintained a Buy rating and projected strong new order growth and faster CDMO conversion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment